For US Healthcare Providers Only

For US Healthcare Providers Only

TOP

IMPORTANT SAFETY INFORMATION

Indication

Makena is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history

Important Safety Information for Makena
(hydroxyprogesterone caproate injection)

  • Do not use Makena in women with any of the following conditions:

You are now leaving makenahcp.com. AMAG Pharmaceuticals is not responsible for the information contained in any of the linked third-party sites. Please review the site's Privacy Policy and Terms of Use, as AMAG's policies do not apply to third-party sites.

Cancel Continue

You are now leaving makenahcp.com. AMAG Pharmaceuticals is not responsible for the information contained in any of the linked third-party sites. Please review the site's Privacy Policy and Terms of Use, as AMAG's policies do not apply to third-party sites.

Cancel Continue

There may be some confusion about the current status of Makena. Makena remains available to patients and prescribers. If you have questions or concerns about receiving your therapy as prescribed, consult your healthcare provider.

If you have questions about the status of your prescription, would like to talk with a Care Manager about participation in our patient support program, or would like more information about the FDA hearing discussing Makena, please call 1-800-847-3418, Monday–Friday from 8:00 AM–8:00 PM ET.